Q1: Is Stage 4 lung cancer curable?

For most patients, Stage 4 lung cancer cannot be cured. However, some with specific genetic changes respond well to targeted therapy and may have long periods of disease control. In some cases, survival can exceed five years.

Q2: How long can you live with Stage 4 lung cancer?

It varies widely. Without treatment, median survival is around 7 months for NSCLC. With osimertinib for EGFR-mutant NSCLC, median overall survival exceeds 38 months. Some patients live 5 to 10 years or more.

Q3: What is the best treatment for Stage 4 lung cancer?

There is no single best treatment. It depends entirely on biomarker testing results. Targeted therapy is preferred if an actionable mutation is present. Immunotherapy with or without chemotherapy is standard for patients without targetable mutations.

Q4: What happens when Stage 4 lung cancer spreads to the brain?

Brain metastases are treated with stereotactic radiosurgery (1 to 3 lesions), whole-brain radiation (multiple lesions), or targeted agents with good CNS penetration such as osimertinib or alectinib.

Q5: Does palliative care mean stopping treatment?

No. Palliative care runs alongside active treatment and focuses on symptoms, pain, and quality of life. It can begin at diagnosis and is recommended for all Stage 4 patients regardless of other treatment choices.

Stage 4 Lung Cancer: Life Expectancy and Treatment

What Is Stage 4 Lung Cancer?

Stage 4 lung cancer means the cancer has spread outside the lungs to other parts of the body, like the brain, liver, bones, or adrenal glands. It usually cannot be cured, but treatment can still help slow it down, relieve symptoms, and help people live longer. Newer options, including targeted therapy and immunotherapy, are helping some patients do better than before.

Stage 4, also called metastatic lung cancer, means cancer cells have travelled through the bloodstream or lymphatic system to form new tumours in other parts of the body. It is the most common stage at diagnosis because the disease often causes no symptoms until advanced.

Stage 4A vs Stage 4B

Stage 4A: Cancer has spread to the opposite lung, or malignant cells are found in fluid surrounding the lung (pleural effusion) or heart (pericardial effusion), or there is one metastasis in a single distant organ.
Stage 4B: Cancer has spread to multiple locations in one or more distant organs. For example, several brain metastases or involvement of both liver and bone.

Common Metastatic Sites and Symptoms

The brain, bones, liver, adrenal glands, and opposite lung are the most often affected organs by stage 4 lung cancer. Compared to adrenal or bone spread, brain and liver metastases are linked to a lower survival rate. Symptoms at this stage typically include persistent cough, chest pain, unexplained weight loss, fatigue, shortness of breath, and, if the brain is involved, headaches or confusion.

Stage 4 Lung Cancer Life Expectancy

Five-Year Survival Rates

According to the American Cancer Society (SEER data, 2015 - 2021):

Distant-stage NSCLC: approximately 12% five-year relative survival rate
Distant-stage SCLC: approximately 4% five-year relative survival rate

These are population averages based on patients treated several years earlier. Outcomes for patients starting treatment today are likely to be better.

Median Survival by Treatment

Without treatment: approximately 7 months (NSCLC); 2 to 4 months (SCLC)
Chemotherapy alone: median survival 8 to 10 months for NSCLC
Immunotherapy (eligible patients): median survival approximately 18.4 months in select first-line studies; immunotherapy is associated with an average 10.7 month survival gain at Stage 4
Targeted therapy (EGFR-mutant NSCLC, osimertinib): median overall survival exceeding 38 months in pivotal trials

A subset of Stage 4 NSCLC patients, estimated at 10 to 15%, survive five years or more, particularly those with actionable mutations on matched targeted therapy.

Factors That Affect Survival

Actionable gene mutations (EGFR, ALK, ROS1, KRAS G12C): best long-term outcomes when matched targeted therapy is used
PD-L1 expression: high expression predicts better immunotherapy response
Performance status: patients who are active and able to care for themselves (ECOG 0 to 1) tolerate treatment better and live longer
Number of metastatic sites: fewer sites (oligometastatic disease) is associated with better outcomes
Brain or liver metastases are linked to shorter survival than other sites
Age and coexisting conditions influence treatment tolerability

Stage 4 Lung Cancer Treatment Options

Treatment for Stage 4 lung cancer usually starts with detailed testing of the tumour or a blood sample. These tests help find specific changes in the cancer that doctors can use to choose the most suitable treatment.

Targeted Therapy

Targeted therapy is frequently the initial treatment option for individuals whose tumors contain particular genetic alterations. These are typically oral medications that target the signals that promote the growth of the malignancy. Typical choices consist of:

EGFR mutations: osimertinib (preferred first-line), erlotinib, gefitinib, or afatinib
ALK rearrangements: alectinib, brigatinib, or lorlatinib
ROS1 rearrangements: crizotinib or entrectinib
KRAS G12C: sotorasib or adagrasib
MET exon 14 skipping: capmatinib or tepotinib
BRAF V600E: dabrafenib plus trametinib

These treatments often keep the cancer under control for longer and are usually easier to tolerate than standard chemotherapy.

Immunotherapy

For patients without actionable mutations, PD-1/PD-L1 checkpoint inhibitors are central to treatment. The key agents are pembrolizumab, nivolumab, atezolizumab, and durvalumab.

High PD-L1 expression (≥50%): pembrolizumab alone may be used as first-line therapy
Low or absent PD-L1: immunotherapy is combined with platinum-based chemotherapy

For extensive-stage SCLC, first-line treatment is platinum-etoposide chemotherapy combined with atezolizumab or durvalumab.

Chemotherapy

Platinum-based chemotherapy, such as carboplatin or cisplatin combined with paclitaxel, pemetrexed, or gemcitabine, is still a key treatment option, especially when no targetable mutations are found. It is often given along with immunotherapy and may also be used if other treatments stop working. In many cases, it also helps ease symptoms and improve comfort.

Radiation Therapy

Radiation is used at Stage 4 for specific purposes:

Stereotactic radiosurgery (SRS) for 1 to 3 brain metastases
Whole-brain radiation for multiple brain metastases
Palliative radiation to bones to relieve pain
Consolidation radiation to the primary tumour in oligometastatic disease

Palliative Care

Palliative care focuses on enhancing comfort and quality of life from the moment of diagnosis; however, it is sometimes misinterpreted as end-of-life care. It helps manage symptoms like pain, dyspnea, exhaustion, and emotional stress in conjunction with continued therapy. Early initiation of palliative treatment has been demonstrated in studies to enhance everyday well-being and potentially extend life expectancy for those with Stage 4 cancer.

Clinical Trials

As of 2024, over 170 clinical trials are recruiting Stage 4 lung cancer patients in the US alone. Trials are testing next-generation targeted agents, novel immunotherapy combinations, and antibody-drug conjugates. Patients who do not respond to standard treatment should ask their oncologist about trial eligibility.

Conclusion

Stage 4 lung cancer represents a complex and widespread disease, but treatment options today are more advanced than ever before. From targeted therapies to immunotherapy, care is increasingly personalised to improve both survival and daily living. With the right approach, many patients are able to manage the disease more effectively than in the past. If someone you know is dealing with advanced lung cancer, discussing treatment options with our lung cancer specialist will help you guide their care.